Key takeaways
- Four of the twelve are approved medicines: semaglutide, tirzepatide, oxytocin and elamipretide, each for the uses and populations on its own label.
- Four have peer-reviewed controlled studies in people and are not FDA-approved: retatrutide and thymosin alpha 1 in phase 3 trials, GHK-Cu in randomised trials on skin wounds and skin care, and kisspeptin in small studies.
- For BPC-157, TB-500, MOTS-c and KPV we found no peer-reviewed controlled study in people (PubMed, 21 November 2026); BPC-157’s randomised data exist only as conference abstracts, and FDA staff’s searches did not identify clinical studies of MOTS-c or KPV in humans.
- WADA’s 2026 and 2027 Lists name BPC-157, TB-500, kisspeptin and MOTS-c, prohibited at all times; its notes say a peptide not specifically named “may still be prohibited”.
- A grade records study design. Two placebo-controlled phase 3 trials of thymosin alpha 1, in hepatitis B and in sepsis, found no significant effect on their primary outcomes.
01How are the peptides on this page graded?
If you searched for “best peptides”, the honest reply is that the word has no single meaning: it depends on the question, the person and the use. What can be put in order is the evidence. This page takes twelve peptides from our library and grades each by the strongest study design that exists for it.
Within each row, the tier codes are the ones on our guides: T1 a randomised trial in people, T2 a small or uncontrolled human study, T3 an animal study, T4 a cell study. The method is on evidence grades. Compounds that act on growth hormone are not covered on this page.
02Which peptides have the strongest study designs behind them?
Twelve peptides, strongest evidence first. Every cell was checked against its source on 21 November 2026. A grade describes study design. It is not a recommendation, and it says nothing about any product sold under the same name.
| Peptide | What it is | Strongest study design that exists | Approval status (where we checked) | Sport status (WADA) |
|---|---|---|---|---|
| Semaglutide | A GLP-1 receptor agonist, described on its label as a GLP-1 analog. A prescription medicine (Ozempic, Rybelsus, Wegovy). | Tier 1. T1, approved. Randomised, double-blind, placebo-controlled trials; STEP 1 enrolled 1,961 adults without diabetes for 68 weeks. | Yes. FDA first approved it in 2017 (Ozempic). Wegovy’s US label covers, among other uses, reducing excess body weight in adults and children aged 12 and over with obesity, and in adults with overweight who have a weight-related condition, with diet and physical activity. Research-grade material sold under the name is not these medicines. | Not named on the 2026 or 2027 Prohibited List. On WADA’s 2027 Monitoring Program, which covers substances “not on the Prohibited List” that WADA wishes to monitor. |
| Tirzepatide | One peptide that acts on two receptors, GIP and GLP-1. A prescription medicine (Mounjaro, Zepbound). | Tier 1. T1, approved. Phase 3, randomised, double-blind trials; SURMOUNT-1 enrolled 2,539 adults without diabetes for 72 weeks. | Yes. Mounjaro’s US label includes blood-sugar control in adults and children aged 10 and over with type 2 diabetes. Zepbound’s covers reducing excess body weight in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnoea in adults with obesity. Research-grade material is not these medicines. | Not named on the 2026 or 2027 Prohibited List. On WADA’s 2027 Monitoring Program, which covers substances “not on the Prohibited List” that WADA wishes to monitor. |
| Oxytocin | A hormone of nine amino acids. Synthetic oxytocin is a prescription medicine (Pitocin). | Tier 1. Approved. This row rests on its US label, not on individual trials. | Yes. Pitocin’s US label covers starting or improving contractions of the uterus when there is a medical reason for delivery, and controlling bleeding after birth. It states that Pitocin “is not indicated for elective induction of labor”. | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. |
| Elamipretide (SS-31) | A peptide of four amino acids that binds cardiolipin in mitochondria. The active ingredient of Forzinity. | Tier 1. T1, small. A randomised, double-blind, placebo-controlled crossover trial in 12 people with Barth syndrome, in which it “was not superior to placebo” on the two primary endpoints, and an open-label extension. A phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints. | Yes, under accelerated approval (19 Sep 2025): “to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”, based on an intermediate endpoint. Products sold online as SS-31 are not that medicine. | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. |
| Retatrutide | An investigational drug from Eli Lilly: one peptide that acts on the GIP, GLP-1 and glucagon receptors. Not an approved medicine. Every published trial tested Lilly’s product; material sold online under the name has not been through those trials. | Tier 2. T1, investigational. Phase 3, randomised, double-blind, placebo-controlled trial (TRIUMPH-1): 2,339 adults with obesity and no diabetes, 80 weeks; funded by the developer. | Drugs@FDA lists no product (21 Nov 2026). FDA says it “cannot be used in compounding under federal law” and has “not been found safe and effective for any condition”. | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. |
| Thymosin alpha 1 | A peptide of 28 amino acids, also called thymalfasin. | Tier 2. T1. Placebo-controlled phase 3 trials in 97 adults with chronic hepatitis B (1999) and 1,106 adults with sepsis (2025); neither found a significant effect on its primary outcome. | Not FDA-approved. FDA’s 2024 review cites approvals in Italy, India and Hong Kong, and describes Zadaxin as “a finished drug product available in other countries”. Products sold online as thymosin alpha 1 are not those medicines. | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. |
| GHK-Cu | A peptide of three amino acids (glycine, histidine, lysine) bound to copper. | Tier 2. T1. Randomised trials on skin wounds and on skin care. The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing (13 completers, 2006): blinded and computer assessments found no significant difference between groups; a patient questionnaire did differ (P = .04). | No medicine containing it appears in Drugs@FDA (21 Nov 2026). Cosmetic ingredients do not require FDA approval before sale. | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. |
| Kisspeptin | A hormone encoded by the KISS1 gene, with forms from kisspeptin-54 down to kisspeptin-10. | Tier 2. T2. Human genetics studies, and small studies that measured hormone levels, such as a double-blind, placebo-controlled crossover study in 6 men (2005). | FDA staff, 2024: “There is no approved product in any country containing kisspeptin-10”. Kisspeptin-10 has been in FDA’s compounding Category 2 since 29 Sep 2023. | Named in class S2, in an entry for males (S2.2.1); prohibited at all times. |
| BPC-157 | A synthetic peptide of 15 amino acids. | Tier 3. Mostly T3 and T4: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical. In people (T2), the only randomised, placebo-controlled data are conference abstracts from 2002 to 2005. A randomised phase 2 trial is recruiting. | FDA staff’s 2026 search found it in no approved product in any country. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval. | Named in class S0, non-approved substances; prohibited at all times. |
| TB-500 | A synthetic fragment, seven amino acids long, of the protein thymosin β4. | Tier 3. T3 and T4. FDA staff found no article in which it was given to humans; a later 2026 report describes three patients given it with other agents, without a control group. A randomised phase 1/2 trial is recruiting. | FDA staff found no approved product containing it in Canada, Australia, the United Kingdom or seven other European countries, and none authorised by the European Medicines Agency. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval. | Named in class S2: “Thymosin-β4 and its derivatives e.g. TB-500”; prohibited at all times. |
| MOTS-c | A peptide of 16 amino acids encoded in mitochondrial DNA, first reported in 2015. | Tier 3. T3 and T4 for studies that gave it. FDA staff “did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans”. A randomised phase 2 trial is recruiting. | Drugs@FDA lists no product (21 Nov 2026), and FDA staff found none listed by the European Medicines Agency. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval. | Named in class S4, metabolic modulators (S4.4.1); prohibited at all times. |
| KPV | A peptide of three amino acids (lysine, proline, valine). FDA’s 2026 briefing describes it as a fragment of the hormone α-MSH. | Tier 3. T3 and T4: mouse colitis models and human cells in a dish (2008). FDA staff’s search “did not identify data, such as clinical studies, on the use of KPV in humans”, and ClinicalTrials.gov lists no trial (21 Nov 2026). | Drugs@FDA lists no product (21 Nov 2026), and FDA staff found none listed by the European Medicines Agency. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval. | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. |
Guides: semaglutide, tirzepatide, oxytocin, SS-31, retatrutide, thymosin alpha 1, GHK-Cu, kisspeptin, BPC-157, TB-500, MOTS-c, KPV. Sport rules in full: peptides and anti-doping.
03What do the three tiers mean?
The tiers are about what has been tested, and how. Inside a tier, rows run from the stronger study designs to the weaker.
Approved medicine
A regulator has reviewed the evidence and approved a product for the uses on its label. Four of the twelve: semaglutide, tirzepatide, oxytocin and elamipretide. The approval belongs to the product, not to everything sold under the compound’s name.
Controlled studies in people, no approval
Peer-reviewed controlled studies in people exist, from phase 3 trials (retatrutide, thymosin alpha 1) to randomised trials on skin wounds and skin care (GHK-Cu) and small hormone studies (kisspeptin). None is an FDA-approved medicine.
No peer-reviewed controlled study in people
BPC-157, TB-500, MOTS-c and KPV. Most studies that gave them are in animals and cells. In people, BPC-157 has small uncontrolled studies and randomised data published only as conference abstracts, and one uncontrolled report describes three patients given TB-500 with other agents. We found no peer-reviewed controlled study of any of the four in people (PubMed, 21 November 2026).
04What can’t an evidence grade tell you?
Whether it works.
A grade records the design of a study, not its finding. Two placebo-controlled phase 3 trials of thymosin alpha 1 found no significant effect on their primary outcomes.
Whether it is safe.
Design says little about harm. Approved labels carry warnings, and for BPC-157 FDA staff found “insufficient clinical safety information to characterize the safety profile”. See are peptides safe.
What is in a vial.
Evidence belongs to the molecule a study tested. Whether a given vial contains that molecule is a separate question, and only a lab test of that sample answers it.
What the rules are where you live.
Approval and sport status are two facts among several, and rules differ by country. See are peptides legal.
Why photos and testimonials cannot stand in for any of these: do peptides work?
05What we don’t know
- What the trials now recruiting will show for BPC-157, TB-500 and MOTS-c. Each has a randomised trial registered, with nothing posted yet.
- Whether retatrutide will be approved. It is investigational, and Drugs@FDA lists no product (21 November 2026).
- Whether elamipretide’s accelerated approval will be confirmed. Its label says continued approval “may be contingent upon verification and description of clinical benefit in a confirmatory trial”.
- How compounds outside this page would grade. Twelve are covered here; each guide in our library carries its own grade.
How the prescription route is regulated: what is peptide therapy? New studies and rule changes, once a week: the 6:00 brief.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not medical or legal advice. For anything about your health, a doctor who knows you is the right call.